Monday in MedTech: board shuffles, software patches, and a neonatal device acquisition you probably missed. Stryker's CEO is joining a rival's board. Fresenius quietly pushed a software fix for an infusion pump that could interrupt patient treatment. A startup making light-therapy swaddles for jaundiced newborns just got acquired. And we're taking a hard look at the surgical robotics war, because it's about to get a lot more interesting. Issue #3 starts now.
Top Stories
Story 01
Stryker CEO Kevin Lobo has been appointed to the GE HealthCare board of directors, a notable cross-company governance move in MedTech. Lobo has led Stryker since 2012, overseeing the company's transformation from an orthopedic-focused manufacturer into a broad MedTech platform covering surgical equipment, neurotechnology, and vascular devices. His addition to GE HealthCare's board reflects the growing overlap between imaging, surgical robotics, and hospital capital equipment markets.
Why This Matters
When the CEO of the world's largest pure-play surgical device company joins an imaging company's board, the market reads it as a signal. Imaging-guided surgery and AI-assisted procedures are the next integration frontier. Cross-board governance often precedes commercial partnerships. Watch for joint announcements in OR workflow and robotic-guided imaging over the next 18 months.
Governance
Leadership
Story 02
Fresenius Kabi issued a software release for its Ivenix large-volume infusion pump system to address bugs that could interrupt medication delivery during patient treatment. Infusion pump software failures are among the most closely watched issues in hospital safety, pumps control the rate and volume of intravenous fluids and drugs, and any interruption can have direct patient consequences. Fresenius says the update addresses the issues and users have been notified through their hospital biomedical engineering teams.
Patient Safety
Software Update
Story 03
Natus Sensory has acquired TheraB Medical, the maker of the SnugLit, an FDA 510(k)-cleared wearable phototherapy swaddle for treating neonatal jaundice. The device wraps around a newborn like a blanket and delivers the blue-spectrum light therapy needed to break down excess bilirubin in the bloodstream, eliminating the need for traditional bili-lamp incubators. The acquisition expands Natus's newborn care portfolio with a device that's more mobile and comfortable for both infants and families.
FDA 510(k)
Acquisition
Story 04
AtriCure participated in a fireside chat at the Citizens Life Sciences Conference on March 10, presenting its clinical pipeline and strategy for expanding its leadership in surgical treatment of atrial fibrillation. AtriCure makes cryoablation and radiofrequency ablation devices used in hybrid surgical procedures, a growing market as electrophysiologists and cardiac surgeons increasingly collaborate on complex AFib cases. The company's left atrial appendage (LAA) management device also remains one of the top surgical alternatives to long-term blood thinners.
Cardiac
Pipeline
Know someone in MedTech? Forward this to a colleague. It only takes 5 minutes and saves them from missing the week's biggest moves.
Market Movers
| Ticker | Company | Price | Wk Change |
|---|
| ISRG | Intuitive Surgical | $522.80 | ▲ 1.3% |
| SYK | Stryker | $358.40 | ▲ 0.6% |
| BDX | BD (Becton Dickinson) | $234.80 | ▼ 0.9% |
| JNJ | Johnson & Johnson | $156.80 | ▲ 0.6% |
| ABT | Abbott | $140.60 | ▼ 0.9% |
| ZBH | Zimmer Biomet | $108.60 | ▼ 0.5% |
| BSX | Boston Scientific | $105.10 | ▲ 0.6% |
| GEHC ★ | GE HealthCare | $93.20 | ▲ 3.2% |
| MDT | Medtronic | $89.30 | ▲ 2.4% |
| EW | Edwards Lifesciences | $70.10 | ▲ 1.0% |
★ Top Mover of the week (biggest % change). Sorted by stock price, highest to lowest. Data shown for illustrative purposes. Prices reflect approximate close, week of March 9, 2026.
Deep Dive
The Surgical Robotics War in 2026: Intuitive Surgical vs. Medtronic Hugo vs. J&J Ottava
For two decades, Intuitive Surgical had the operating room robotic surgery market almost entirely to itself. The da Vinci system is in over 8,600 hospitals. Surgeons were trained on it. Hospitals built their surgical programs around it. Then came Hugo, then Ottava, and now the market is finally entering a genuine competitive phase. Here's what each player brings to the table.
- Intuitive Surgical: The installed base is the moat. Intuitive's advantage isn't just the da Vinci system, it's the training ecosystem, the disposable instrument revenue, and the software data platform built on 25+ years of procedures. A hospital switching from da Vinci isn't just buying a new robot, they're retraining their entire surgical team. That friction is Intuitive's best defense.
- Medtronic Hugo: Open architecture, competitive pricing. Hugo was cleared for urological procedures in December 2025 and is now running its first U.S. cases at Cleveland Clinic. Medtronic's strategy is open architecture, letting third-party software and data systems integrate with Hugo, rather than locking hospitals into Medtronic's own ecosystem. Pricing is reported to be meaningfully lower than da Vinci, which is a real lever in cost-conscious health systems.
- J&J Ottava: The challenger with the deepest pockets. Johnson & Johnson has submitted Ottava to the FDA for soft-tissue surgery, the core market where da Vinci dominates. J&J's global sales force, existing hospital relationships, and balance sheet make it the most formidable challenger. Clearance timing will be the key variable.
Bottom line: Intuitive isn't going away, but it's entering its first real competitive cycle. Watch Hugo's launch in 2026 and J&J's FDA clearance timeline. In five years, the surgical robotics market will look fundamentally different than it does today.
Industry Shifts
Shift 01
As Danaher's planned acquisition of Masimo moves forward, analysts are examining what the deal means for hospital monitoring markets. Masimo is best known for its noninvasive vital signs monitoring technology, particularly pulse oximetry, used in ICUs, operating rooms, and post-op recovery. Danaher's acquisition would combine Masimo's hospital-facing hardware with Danaher's growing diagnostics and analytical instruments business, creating a more integrated clinical data platform.
M&A
$9.9B
Shift 02
Stereotaxis, which received FDA approval in January 2026 for its robotically navigated magnetic ablation catheter, is accelerating commercialization ahead of the Heart Rhythm 2026 conference in April. The company uses magnetic fields to precisely navigate the catheter tip inside the heart chambers, reducing the need for manual manipulation during complex ablation procedures. CEO David Fischel has indicated the April conference as the latest natural point for transitioning to a full U.S. commercial launch.
FDA Approved
Cardiac Robotics
Fun Fact & Trivia
Fun Fact
The Watchman device, a small plug implanted in the heart's left atrial appendage to prevent stroke in AFib patients who can't take blood thinners long-term, has been implanted in more than 150,000 patients worldwide since FDA clearance in 2015, according to Boston Scientific. The company has reported an estimate that the device may have helped prevent more than 15,000 strokes based on its own internal analysis. The procedure takes about an hour and is done through a catheter, no open-heart surgery required. (Source: Boston Scientific)
MedTech Trivia
What does "510(k)" refer to in FDA medical device submissions?
👇 Scroll to the footer for the answer
Sponsor
